Back

Long-term efficacy and safety of hydroquinidine in patients with Brugada syndrome

29 August 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Risk of Sudden Cardiac Death in Patient with Ion Channel Disorders Antiarrhythmic Drug Treatment ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Filippo Angelini

Hospital Citta Della Salute e della Scienza di Torino, Turin (Italy)

5 More presentations in this session

Presentation thumbnail
ICD implantation and device therapy: Fabry vs hypertrophic cardiomyopathy
Doctor R. Vijapurapu (Stoke-on-Trent, GB)
Abstract Slides
Presentation thumbnail
Splice site mutation of LMNA causes severe dilated cardiomyopathy via strong dominant reduction of total lamin expression
Doctor K. Kato (Otsu, JP)
Abstract Slides
Presentation thumbnail
Role of an extensive diagnostic work-up in the detection of concealed cardiomyopathies in athletes with premature ventricular complexes and implications for sports' eligibility assessment
Doctor P. Compagnucci (Ancona, IT)
Abstract Slides
Presentation thumbnail
KCNQ1 V141M and Short QT Syndrome: Are we dealing with a different entity?
Doctor G. Garcia Ordonez (Guadalajara, MX)
Abstract Slides
Presentation thumbnail
Molecular mechanism of a new cardiac syndrome associated with a regulatory element deletion of chromosome 4q25
Ms M. Baudic (Nantes, FR)
Abstract Slides

Access the full session

Session thumbnail
Risk of Sudden Cardiac Death in Patient with Ion Channel Disorders

The Event

Event poster

ESC Congress 2020

29 August 2020 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and limitations of quinidine therapy in patients with Brugada Syndrome
3 September 2019
thumbnail
Congress Presentation
Long-term QT interval analysis for real world patients with Insertable cardiac monitors taking antiarrhythmic drugs
8 April 2024
thumbnail
Congress Presentation
Betablockers or calcium channel blockers in hypertrophic cardiomyopathy
22 May 2023
thumbnail
Congress Presentation
A prospective, multicenter, nationwide, observational study of flecainide controlled release on the quality of life of patients with atrial fibrillation in Greece, the REFLEC-CR study
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources